CMN Weekly (10 September 2021)

Some of the best links we picked up around the internet

By: Karen O'Hanlon Cohrt - Sep. 10, 2021

Top picks

Clinical

Industry

Research

  • Scientists from multiple institutions in the US have stablished an in vivo strategy to evolve and stringently select capsid variants of adeno-associated viruses (AAVs) that enable potent delivery to desired tissues. Using this approach, the team has identified a class of RGD motif-containing capsids that transduces muscle with superior efficiency and selectivity after injection into mice and non-human primates. Experiments in mouse models of genetic muscle disease revealed that the engineered vectors had enhanced potency and therapeutic efficacy compared to naturally occurring AAV vectors. The work was published in Cell yesterday.
  • Researchers from the US and Switzerland demonstrate programmable RNA targeting in mammalian cells with the single-protein CRISPR effector Cas7-11, a class 1 CRISPR–Cas system that originates from the fusion of a putative Cas11 domain and multiple Cas7 subunits. The findings were published in Nature earlier this week.
  • Researchers at University of California San Diego have developed pgSIT, a new scalable genetic control system that uses a CRISPR-based approach to engineer deployable mosquitoes that can suppress populations of malaria-carrying mosquitoes. The findings were published in Nature Communications today.
  • Research led by Feng Zhang at Massachusetts Institute of Technology has uncovered a widespread class of transposon-encoded RNA-guided nucleases which they name OMEGA (Obligate Mobile Element Guided Activity), with strong potential for biotechnological development. The team made the discovery while exploring the evolutionary origins of an enzyme used in the CRISPR genome-editing system. The findings were published in Science yesterday.

Podcasts and webinars

Reviews

COVID-19

  • An article published in Science Advances this week describes a universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering. Using bacteriophage T4, the researchers behind the work engineered a pipeline of vaccine candidates by incorporating various viral components into appropriate compartments of the phage nanoparticle. Without any adjuvant, the vaccine stimulated robust immune responses in animals.
  • Researchers in China have developed a new CRISPR-Cas12a-based diagnostic platform through a Raman transducer generated by Raman enhancement effect. The new platform is called SERS-CRISPR (S-CRISPR), and it uses high-activity noble metallic nanoscopic materials to increase the sensitivity of detection of SARS-CoV-2 RNA nucleic acids, without the need for amplification. The findings wre published in Journal of Nanotechnology this week.

Jobs

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

CLINICAL TRIALS
Multiple myeloma, MM (NCT04960579)
Sponsors:
Poseida Therapeutics, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Non-small Cell Lung Cancer,NSCLC, (NCT03525782)
Sponsors:
First Affiliated Hospital of Guangdong Pharmaceutical University
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine